{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:02:57Z","timestamp":1792735377301,"version":"4.5.0"},"reference-count":29,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Manchester National Institute for Health Research Manchester Biomedical Research Centre","award":["IS-BRC-1215-20007"],"award-info":[{"award-number":["IS-BRC-1215-20007"]}]},{"name":"Yorkshire Cancer Research","award":["L403"],"award-info":[{"award-number":["L403"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2026,5,28]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung cancer (LC) is the most common cause of cancer death in the UK and worldwide, but screening with low-dose CT (LDCT) reduces LC deaths. The UK National Screening Committee has recommended nationwide roll-out of LDCT screening, but the optimal risk thresholds for eligibility remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a cost-effectiveness analysis in the Yorkshire Lung Screening Trial (YLST) population comparing three eligibility criteria: US Preventive Services Task Force (USPSTF)\n                      <jats:sub>2013<\/jats:sub>\n                      , Prostate Lung Colorectal and Ovarian study (PLCO)\n                      <jats:sub>M2012<\/jats:sub>\n                      \u22651.51%\u2009and Liverpool Lung Project model (LLP)\n                      <jats:sub>v2<\/jats:sub>\n                      \u22655%. A Markov model estimated a no-screening counterfactual. Scenario analyses assessed how increasing PLCO\n                      <jats:sub>M2012<\/jats:sub>\n                      (1.51%\u20137%) and LLP\n                      <jats:sub>v2<\/jats:sub>\n                      (5%\u20139%) thresholds affected LC detection, costs and quality-adjusted life years (QALYs). Payouts per detected LC were calculated using mortality and utility estimates from the literature and cost data from the trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Incremental cost-effectiveness ratios (ICERs) versus no screening were \u00a33949 (USPSTF\n                      <jats:sub>2013<\/jats:sub>\n                      ), \u00a33797 (LLP\n                      <jats:sub>v2<\/jats:sub>\n                      \u22655%) and \u00a34013 (PLCO\n                      <jats:sub>M2012<\/jats:sub>\n                      \u22651.51%). PLCO\n                      <jats:sub>M2012<\/jats:sub>\n                      yielded the largest numbers screened and LCs detected, most QALYs gained and highest incremental net monetary benefit. Raising LLP\n                      <jats:sub>v2<\/jats:sub>\n                      and PLCO\n                      <jats:sub>M2012<\/jats:sub>\n                      thresholds reduced both ICERs and QALYs gained.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      All three screening eligibility criteria are cost-effective according to the UK\u2019s willingness to pay threshold of \u00a320 000\/QALY. Within the range of thresholds observed in YLST, PLCO\n                      <jats:sub>M2012<\/jats:sub>\n                      thresholds between \u22651.51%\u2009and \u22654% offered the most efficient cost\u2013benefit trade-offs. Evidence suggests that lowering thresholds further would detect more LC cases while remaining cost-effective. These findings support the criteria implemented in YLST, but do not by themselves identify the optimal screening threshold for the wider UK population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN42704678\">ISRCTN42704678<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223859","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:20:38Z","timestamp":1782408038000},"page":"thorax-2025-223859","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative cost-effectiveness of screening for lung cancer using different risk scores and thresholds: the Yorkshire Lung Screening Trial"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"isrctn42704678","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-0934","authenticated-orcid":false,"given":"Yingying","family":"Zhang","sequence":"first","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hinde","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona S","family":"Marshall","sequence":"additional","affiliation":[{"name":"Leeds Institute of Health Sciences, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hancock","sequence":"additional","affiliation":[{"name":"Leeds Institute of Health Sciences, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Simmonds","sequence":"additional","affiliation":[{"name":"Leeds Institute of Health Sciences, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Soares","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian","family":"Gabe","sequence":"additional","affiliation":[{"name":"Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vulkan","sequence":"additional","affiliation":[{"name":"Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-4813","authenticated-orcid":false,"given":"Philip A","family":"Crosbie","sequence":"additional","affiliation":[{"name":"Division of Immunology, Immunity to Infection and Respiratory Medicine, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8157-0803","authenticated-orcid":false,"given":"Matthew E J","family":"Callister","sequence":"additional","affiliation":[{"name":"Leeds Institute of Health Sciences, University of Leeds, Leeds, UK"},{"name":"Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026062510202831000_thorax-2025-223859v1.1","doi-asserted-by":"crossref","first-page":"102693","DOI":"10.1016\/j.canep.2024.102693","article-title":"Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"2026062510202831000_thorax-2025-223859v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102873"},{"key":"2026062510202831000_thorax-2025-223859v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911793"},{"key":"2026062510202831000_thorax-2025-223859v1.4","unstructured":"Lung Cancer Policy Network . Interactive map of lung cancer screening. Available: https:\/\/www.lungcancerpolicynetwork.com\/interactive-map-of-lung-cancer-screening\/ [Accessed 11 Feb 2025]."},{"key":"2026062510202831000_thorax-2025-223859v1.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1117"},{"key":"2026062510202831000_thorax-2025-223859v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209120"},{"key":"2026062510202831000_thorax-2025-223859v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604158"},{"key":"2026062510202831000_thorax-2025-223859v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211776"},{"key":"2026062510202831000_thorax-2025-223859v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00590-8"},{"key":"2026062510202831000_thorax-2025-223859v1.10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jtho.2024.12.016","article-title":"Prospective Evaluation of Lung Cancer Screening Eligibility Criteria and Lung Cancer Detection in the Yorkshire Lung Screening Trial","volume":"20","author":"Gabe","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026062510202831000_thorax-2025-223859v1.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1077"},{"key":"2026062510202831000_thorax-2025-223859v1.12","doi-asserted-by":"publisher","DOI":"10.3310\/hta20220"},{"key":"2026062510202831000_thorax-2025-223859v1.13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2018.10.029","article-title":"The cost-effectiveness of the Manchester \u201clung health checks\u201d, a community-based lung cancer low-dose CT screening pilot","volume":"126","author":"Hinde","year":"2018","journal-title":"Lung Cancer (Auckl)"},{"key":"2026062510202831000_thorax-2025-223859v1.14","unstructured":"UK National Screening Committee . Final report on the cost-effectiveness of low dose computed tomography (LDCT) screening for lung cancer in high risk individuals. UK Government; 2022a. Available: https:\/\/view-health-screening-recommendations.service.gov.uk\/document\/f0d91153-a2b9-4c13-953e-8a5f60abab0a\/download"},{"key":"2026062510202831000_thorax-2025-223859v1.15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-6-201309170-00690"},{"key":"2026062510202831000_thorax-2025-223859v1.16","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2771."},{"key":"2026062510202831000_thorax-2025-223859v1.17","unstructured":"NICE health technology evaluations: the manual (PMG36). London, UK National Institute for Health and Clinical Excellence (NICE); 2022."},{"key":"2026062510202831000_thorax-2025-223859v1.18","unstructured":"National cost collection 2022\/23. NHS England and NHS improvement; 2023. Available: https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/"},{"key":"2026062510202831000_thorax-2025-223859v1.19","unstructured":"Morgan E , Roz\u00e9e S . National life tables\u2013life expectancy in the UK: 2017 to 2019. Office of National Statistics; 2020."},{"key":"2026062510202831000_thorax-2025-223859v1.20","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X15570364"},{"key":"2026062510202831000_thorax-2025-223859v1.21","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.cllc.2021.09.006","article-title":"Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data","volume":"23","author":"Kuehne","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2026062510202831000_thorax-2025-223859v1.22","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ijc.34746","article-title":"Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland","volume":"154","author":"Tomonaga","year":"2024","journal-title":"Int J Cancer"},{"key":"2026062510202831000_thorax-2025-223859v1.23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28833"},{"key":"2026062510202831000_thorax-2025-223859v1.24","unstructured":"Buxton J . National life tables\u2013life expectancy in the UK: 2018 to 2020. Office for National Statistics; 2021."},{"key":"2026062510202831000_thorax-2025-223859v1.25","unstructured":"Zhang Y , Hinde S , Marshall C , et al . The cost of lung cancer screening and uptake maximisation: findings from the yorkshire lung screening trial. In: Jones KCH , ed. Unit costs of health and social care 2024 manual. Personal Social Services Research Unit (PSSRU), University of Kent, 2025."},{"key":"2026062510202831000_thorax-2025-223859v1.26","unstructured":"England, N. H. S . Standard protocol prepared for the targeted lung health checks programme: targeted screening for lung cancer with low radiation dose computed tomography. National Cancer Programme; 2019. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2019\/02\/B1646-standard-protocol-targeted-lung-health-checks-programme-v2.pdf"},{"key":"2026062510202831000_thorax-2025-223859v1.27","unstructured":"UK National Screening Committee . Lung cancer screening recommendation. 2022b. Available: https:\/\/view-health-screening-recommendations.service.gov.uk\/lung-cancer\/ [Accessed 24 Feb 2025]."},{"key":"2026062510202831000_thorax-2025-223859v1.28","unstructured":"Jones KC . Unit costs of health and social care 2023 manual. Technical report. Personal social services research unit (university of Kent) & centre for health economics (university of York), Kent, UK. 2024."},{"key":"2026062510202831000_thorax-2025-223859v1.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037075","article-title":"Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk","volume":"10","author":"Crosbie","year":"2020","journal-title":"BMJ Open"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:20:44Z","timestamp":1782408044000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":29,"alternative-id":["10.1136\/thorax-2025-223859"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223859","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}